Seeking Alpha

maven pharm

maven pharm
Send Message
View as an RSS Feed
View maven pharm's Comments BY TICKER:
Latest  |  Highest rated
  • Baxter prepares to unload $1.45B Baxalta stake [View news story]
    I want to own Baxalta. I just do.
    Sep 2, 2015. 04:32 PM | Likes Like |Link to Comment
  • Baxter prepares to unload $1.45B Baxalta stake [View news story]
    Baxalta appears to be a good investment; intuitively I feel they have good basic research but intuition is not proof positive so I would have to search for more facts. I want to take a position in this company.
    Sep 1, 2015. 07:09 PM | Likes Like |Link to Comment
  • Is Biogen's Stock Plunge Overreaction? [View article]
    I remember about 4 months ago when Biogen skyrocketed to $480.00 per share in days from about $415 on news of the potential of its Alzheimer's drug. Now it is about $300.00. I mean I now emotional response to a drug can have far-reaching effects but these spread it ridiculous. Mr. Arie Goren's article was very informative and as I suspect Biogen -Idec is a good investment vehicle for the long term investor with great growth prospects. If someone had money to buy some shares at this price or below; I would jump at it. There baseline earnings are great; and their is cash in the till to purchase other companies when a deal presents itself.
    Jul 27, 2015. 08:33 AM | 3 Likes Like |Link to Comment
  • Biogen (BIIB) George A. Scangos, Ph.D. on Q2 2015 Results - Earnings Call Transcript [View article]
    DISAPPOINTING. CELGENE AND AMGEN HAVE BROADER APPEAL BASED ON DEALS THEY HAVE MADE WITH NEW EXCITING SMALL INNOVATIVE BIOTECH FIRMS. I HOPE THE MANAGEMENT WILL DO THIS. I OWN THIS STOCK. I WILL BE PATIENT.
    Jul 24, 2015. 02:13 PM | Likes Like |Link to Comment
  • Coca-Cola Q2, Still Chugging Along [View article]
    Coke is so big I imagine they can maneuver their earnings using accounting without anyone really knowing. I have not had a Coke for years. Coke is responsible for making people overweight; even if it is a conscious move to drink or not to drink one. It is responsible for obesity in America. But it is successful at what it does. It is diversifying now; which is good. It is hard to see Coke going anywhere over the next few years; but they generate cash and pay a good dividend so probably long term it is still a good investment if you do not have a conscious.
    Jul 23, 2015. 11:52 AM | Likes Like |Link to Comment
  • Lpath: A Binary Situation With Odds In Investors' Favor [View article]
    Worth a try; it is relativity cheap. Pfizer is a dumb company, You are right. Little biotech firms beating them up. I will keep on following this coming.
    Jul 17, 2015. 08:43 AM | Likes Like |Link to Comment
  • Epizyme Partnership With Celgene Makes It Worth A Look [View article]
    I just was looking for a quote on a company called affymax and it was listed after I entered Aff and I clicked on to it because it had interesting name. I started reading what it was doing as far a biotech research. I occurred to me that Seth Klarman would like the stock. So I bought some and when it went up I bought some more. Than I saw a big French company in biotech was interested in it. The trajectory of this stock has been nothing sort of amazing. I am buying more.
    Jul 17, 2015. 08:38 AM | 2 Likes Like |Link to Comment
  • Epizyme Partnership With Celgene Makes It Worth A Look [View article]
    I found this very interesting biotech stock about 2 months ago and it doubled in price. It is a German biotech company called Affimed and a French biotechnology company has agreed to work with it on a antibody it makes. It appears to be very similar type company to Atara Biotherapeutics. Yesterday it went up over 2 dollars per share. I have a hunch it is going much higher. Check it out.
    Jul 17, 2015. 02:08 AM | 1 Like Like |Link to Comment
  • Epizyme Partnership With Celgene Makes It Worth A Look [View article]
    Extremely well written article and very informative. Good investment analysis and philosophy for biotech investments. Obviously; Celgene will make out well if Epizyme's products are marketable. Thank you Mr. Meyers. I really like this article.
    Jul 13, 2015. 06:18 PM | 3 Likes Like |Link to Comment
  • Aerie Pharma: Was Rocket 1 Really A Failure? [View article]
    Although Timolol is used frequently in glaucoma; a lot of people use lantanoprost and brimodine. Timolol is used less frequently now.
    Jun 20, 2015. 11:25 PM | Likes Like |Link to Comment
  • Aerie Pharma: Was Rocket 1 Really A Failure? [View article]
    These ophthalmic drops if effective are such profitable pharmaceutical agents I would imagine that some of the mega international pharmaceutical companies will jump at the chance of taking over Aerie Pharmaceuticals. That is what will happen. I want to buy a lot of stock in this company. Its the real thing.
    Jun 17, 2015. 11:43 AM | 1 Like Like |Link to Comment
  • Buy Rite Aid During The Current Dip: An Algorithmic Analysis [View article]
    YEAH WITH TODAYS BUSINESS CONDITIONS. I AGREE
    May 11, 2015. 10:47 AM | Likes Like |Link to Comment
  • Buy Rite Aid During The Current Dip: An Algorithmic Analysis [View article]
    sounds right. Bad board members; have been on line for years at this company. That explains why is was $1.00 a share for so long.
    May 11, 2015. 10:45 AM | Likes Like |Link to Comment
  • Buy Rite Aid During The Current Dip: An Algorithmic Analysis [View article]
    Pharmacy benefit managers like Caremark keep on lowering fee per prescription and cost per drug allowance; this makes it difficult for a pharmacy to make profit on prescriptions filled. Walgreen's and maybe CVS bought percentages of different wholesalers. Maybe Walgreen bought Amerisource Bergen. But keeping a pharmacy profitable is much more difficult. Pharmacies will have to offer healthcare services that have nothing to do with prescriptions. I imagine that is why Rite Aid bought Envision and why they are also offering clinics within each store or some of their stores. I guess Rite Aid just must prepare its future as a stand alone pharmacy. That is ok with me.
    May 11, 2015. 10:39 AM | Likes Like |Link to Comment
  • Aerie Pharma: Was Rocket 1 Really A Failure? [View article]
    All these lawsuits do not look too encouraging. The CEO who sold a large amount of stock days before the drug trial become public looks suspicious. But it looks like the drug works; that being true; possibly other pharmaceutical companies will try to vary or modify the chemical structure and create a new patented chemical entity that works similar to Rhopressa and try to get FDA approval.
    People with heart blocks,bradycardia and congestive heart failure can not take timolol. Maybe in 2 years Aerie might come back. By than another company may create a new chemical entity that works similar to Rhopressa and get it approved. Looking forward to the combined effect of Rhopressa and lantanoprost.
    May 8, 2015. 06:24 AM | Likes Like |Link to Comment
COMMENTS STATS
189 Comments
121 Likes